Eledon Pharmaceuticals, Inc.
NASDAQ:ELDNBiotechnology
+$0.11 today
- Market cap
- $171.45M
- Beta
- 0.97
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$0.70
Volume 1.12M
Average 1.37M
ELDN Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Eledon Pharmaceuticals, Inc.NASDAQ: ELDN
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization outflow grows to $0
Q1 FY2026 depreciation & amortization was $0, compared with $0 a year earlier. Trailing-twelve-month depreciation & amortization was $0. Over 3 fiscal years it compounded at -5.7% a year.
Context
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly depreciation & amortization holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 313K USD
- Year-over-year change
- -12.8%
- 4-year CAGR
- +12.6%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 313K | -12.8% |
| FY2024 | 2024-12-31 | 359K | -4.0% |
| FY2023 | 2023-12-31 | 374K | +0.3% |
| FY2022 | 2022-12-31 | 373K | +91.3% |
| FY2021 | 2021-12-31 | 195K | — |
Depreciation & Amortization vs competitors
How ELDN compares with its peers on the latest reported figures
- ELDN's LTM Mar 2026 depreciation & amortization of $0 is the smallest of the 11 companies compared; the peer median is $3.89M.
- Its year-over-year change of -100.0% is the lowest of 11, against a peer median of -5.4%.
- Over three fiscal years its annual growth of -5.7% compares with a peer median of -4.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $12.13M | -8.0% | -4.7% | — | |
| LTM Mar 2026 | $10.73M | -6.1% | +3.6% | 4.7% | |
| LTM Mar 2026 | $8.66M | +9.7% | — | 4.0% | |
| LTM Mar 2026 | $6.86M | +34.4% | -13.4% | 340.1% | |
| LTM Mar 2026 | $4.17M | -34.0% | -5.9% | 10.8% | |
| LTM Mar 2026 | $3.62M | +20.6% | -8.0% | 24.9% | |
| LTM Mar 2026 | $3.61M | -20.6% | -13.1% | 9.9% | |
| LTM Mar 2026 | $416K | +0.0% | +17.0% | — | |
| LTM Mar 2026 | $284K | -92.5% | +29.3% | 4.9% | |
| LTM Mar 2026 | $223K | -4.7% | -1.1% | — | |
| LTM Mar 2026 | $0 | -100.0% | -5.7% | — | |
| Peer median (excluding ELDN) | $3.89M | -5.4% | -4.7% | 9.9% | |
Competitors are the stored peer set for ELDN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (34.51M) | (87.97M) | (116.54M) | (36.18M) | (45.62M) |
| Depreciation & Amortization | 195K | 373K | 374K | 359K | 313K |
| Deferred Income Tax | (2.35M) | 0 | 0 | 431K | 5K |
| Stock-Based Compensation | 7.9M | 8.15M | 6.55M | 13.12M | 10.45M |
| Change in Working Capital | (152K) | 2.37M | (4.92M) | 8.71M | 7.65M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 2.14M | 2.08M | (2.6M) | 7.75M | 6.72M |
| Other Working Capital | (2.3M) | 287K | (2.32M) | 959K | 928K |
| Other Non-Cash Items | 0 | 48.65M | 75.01M | (33.71M) | (35.15M) |
| Operating Cash Flow | (28.91M) | (28.42M) | (39.53M) | (47.27M) | (62.34M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (78.29M) | (156.13M) | (161.13M) |
| Sales of Investments | 0 | 0 | 33M | 85.82M | 171.93M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | (45.29M) | (70.31M) | 10.79M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | (449K) | 0 | 33.02M | 133.31M | 53.58M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 215K | 0 |
| Financing Cash Flow | (449K) | 0 | 33.02M | 133.52M | 53.81M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (29.36M) | (28.42M) | (51.8M) | 15.94M | 2.26M |
| Free Cash Flow | (28.91M) | (28.42M) | (39.53M) | (47.27M) | (62.34M) |
Eledon Pharmaceuticals, Inc.
NASDAQ:ELDN
Intrinsic Alpha fair value
Locked
Current Price
$2.03
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.